Novo Nordisk A/S develops, manufactures and markets medicines for serious chronic diseases, with a core franchise in diabetes care and obesity treatment. News for NVO commonly centers on GLP-1 products such as Wegovy, including FDA approvals for new formulations and indications, U.S. launch and access initiatives, and clinical data tied to weight management, cardiovascular risk factors and metabolic liver disease.
Company updates also cover investigational programs such as CagriSema, pipeline results in related therapeutic areas, patient-safety actions involving compounded semaglutide, collaborations with pharmacy or telehealth channels, and capital-allocation matters such as share repurchase activity.
Novo Nordisk (NVO) reported additional B-share purchases under its existing repurchase programme, covering transactions from 5 to 9 October 2026. Accumulated purchases under the programme initiated on 6 May reached 23,090,000 B shares for DKK 6,758,876,433. That programme covers purchases of up to DKK 11,200,000,010.45 through 1 February 2027.
Across the overall programme, purchases since 4 February totalled 37,849,179 B shares as of 9 October, at an average price of DKK 278.97 and a transaction value of DKK 10,558,876,422. Novo Nordisk expects to repurchase up to DKK 15 billion over the 12-month period beginning 4 February 2026. Treasury holdings reached 51,889,876 B shares, corresponding to 1.2% of share capital.
Novo Nordisk (NVO) reported additional B-share purchases under its existing repurchase programme, bringing programme spending to DKK 6,447,270,879 through 2 October 2026. The programme has accumulated 21,845,000 B shares since its 6 May 2026 launch and allows purchases of up to DKK 11,200,000,010.45 through 1 February 2027.
Across the overall repurchase programme beginning 4 February 2026, purchases reached 36,604,179 B shares for DKK 10,247,270,869, at an average price of DKK 279.95 per share. The company expects to repurchase up to DKK 15 billion over that programme's 12-month period. Treasury holdings now total 50,644,876 B shares, corresponding to 1.1% of share capital.
Novo Nordisk (NVO) announced that the FDA review of denecimig for haemophilia A remains ongoing because of manufacturing facility remediation. The application covers adults and children, with or without inhibitors. A decision had been anticipated in the third quarter of 2026, but the FDA has not communicated a new timeline.
The FDA has identified no deficiencies in the submitted clinical efficacy or safety data. Novo is addressing outstanding manufacturing requirements; the site feedback does not affect other marketed Novo products. Novo says the extended review does not affect its 2026 financial outlook and aims to launch denecimig in the US in the first half of 2027, pending a regulatory decision.
Novo Nordisk (NVO) presented an exploratory STEP UP analysis showing Wegovy reduced liver fat in adults with obesity without diabetes. In a 55-participant subgroup, mean liver fat with pooled injectable semaglutide 7.2 mg and 2.4 mg fell from 8.8% to 3.1% at week 72. Among 26 participants starting above 5% liver fat, 23 (88.5%) reached normal levels below 5%.
The broader analysis pooled 1,919 adults from STEP UP and STEP UP T2D. It was post hoc, meaning conducted after the trials, and liver measures were not pre-specified primary or secondary endpoints. Fewer than 1% met criteria for advanced liver-scarring risk at baseline. Semaglutide 2.4 mg is approved for MASH, an inflammatory fatty liver disease, in the United States, Canada, the United Kingdom, China and other markets; 7.2 mg is not being investigated for MASH. Novo expects part 2 results from its separate ESSENCE MASH trial in 2029.
Novo Nordisk (NVO) presented new CagriSema data at EASD 2026 showing changes in food-related brain responses and organ fat. A 52-week brain-imaging study in adults with overweight or obesity found reduced cravings and food preoccupation at weeks 22 and 52. The estimated body-weight treatment difference versus placebo was a 22.4% reduction at week 52 (p<0.0001).
In the REIMAGINE 1 diabetes imaging sub-study, CagriSema 2.4 mg/2.4 mg reduced abdominal, liver and pancreas fat versus placebo, alongside 14.3% weight reduction at week 40. A post hoc REIMAGINE 2 analysis showed preliminary signs of balanced bone maintenance alongside 14.2% weight reduction at week 68. CagriSema remains investigational.
Novo Nordisk (NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a deal worth up to $2.6 billion.
Novo will obtain exclusive rights to develop, manufacture and commercialise the GLP-1/GIP dual receptor agonist globally, excluding mainland China, Hong Kong, Macao and Taiwan. The agreement includes a $300 million upfront payment, milestone-contingent payments and royalties based on net sales in the licensed territory. Hengrui has approval in China to begin phase 1 trials for weight management and type 2 diabetes; once-weekly oral dosing remains a potential use. Closing is expected in the fourth quarter of 2026, subject to U.S. antitrust clearance and other customary conditions.
Novo Nordisk (NVO) reported further B-share purchases under its repurchase plan of up to DKK 15 billion. It bought shares on each trading day from 21 to 25 September 2026. The programme begun on 6 May has repurchased 20,620,000 B shares for DKK 6,139,842,042, against a cap of DKK 11,200,000,010.45 through 1 February 2027.
Across the wider 12-month plan beginning 4 February 2026, purchases reached 35,379,179 B shares for DKK 9,939,842,031 as of 25 September, at an average price of DKK 280.95 per share. Novo Nordisk holds 49,419,876 B shares in treasury, representing 1.1% of its share capital.
Novo Nordisk (NVO) and UNICEF will expand their global partnership with a four-year childhood overweight and obesity prevention programme from 2027 to 2030, aiming to support a healthier start for more than 80 million children in seven countries.
Novo Nordisk will commit USD 18 million from 2026 to 2030, with funding beginning in 2026 to support programme inception and preparation. The programme will focus on policy and community action in Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya, where most affected children live in low- and middle-income settings.
Interventions include growth monitoring, nutrition and physical activity counselling, peer and family support, community- and facility-based prevention, youth advocacy, basic mental health screening and support, and legislation to promote healthier diets. Delivery will be country-led and anchored in UNICEF’s Centres of Excellence model.
Novo Nordisk (NVO) reports continued execution of its 2026 share repurchase programme, detailing B share buybacks completed through 18 September 2026.
The current programme, running from 6 May 2026 to 1 February 2027, allows repurchases of up to DKK 11,200,000,010.45 and forms part of a broader 12‑month buyback of up to DKK 15 billion starting 4 February 2026. From 14–18 September, the company repurchased a total of 1,090,000 B shares, bringing accumulated purchases under this programme to 19,415,000 B shares for DKK 5,829,922,946. As of 18 September, total repurchases since 4 February amount to 34,174,179 B shares for DKK 9,629,922,935, and Novo Nordisk now holds 48,214,876 B shares (1.1% of share capital) as treasury shares out of total A and B shares of 4,465,000,000.
Novo Nordisk (NVO) reported phase 3 topline results showing once-weekly CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes in the REIMAGINE 5 trial.
CagriSema also delivered a non-inferior HbA1c reduction of 1.71% versus 1.67% for tirzepatide. In the REDEFINE 9 obesity trial, CagriSema 1.0 mg/1.0 mg produced 21.0% weight loss versus 2.0% with placebo at week 68, meeting the primary superiority endpoint and improving prespecified measures such as systolic blood pressure, waist-to-height ratio and fasting lipid profile. Across both trials, CagriSema was well tolerated overall, with a safety profile consistent with earlier studies. Novo Nordisk has filed a CagriSema New Drug Application for weight management with a US FDA decision expected in Q4 2026.